Navigation Links
Oncologists Will Be More Aggressive In Adopting Biosimilars Compared With Other Specialties

BURLINGTON, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that oncologists will be the most aggressive in adopting biosimilars compared with other specialties because of their lower clinical trial requirements. According to Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology, Decision Resources expects biosimilar versions of granulocyte colony-stimulating factor (G-CSF) and monoclonal antibody (MAb) therapies used in oncology to erode more than $7 billion in brand sales in 2019 alone across the U.S., EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan markets.

Primary research reveals U.S oncologists in particular will more rapidly adopt biosimilars compared to their European counterparts. Compared with French and German oncologists, U.S. oncologists will require fewer and shorter Phase III clinical trials before they feel comfortable prescribing biosimilars. The majority of surveyed U.S. oncologists would require one trial lasting 12 months or less for biosimilar G-CSFs and at most two clinical trials lasting two years or less for biosimilar MAbs before they feel comfortable prescribing biosimilars. Surveyed solid-tumor oncologists across countries have higher expectations for clinical trials of biosimilar MAbs than for biosimilar G-CSFs.

Across the U.S., France and Germany, the majority of surveyed oncologists expect to begin prescribing biosimilars within 12 months after launch, contributing to the rapid erosion of branded G-CSFs and MAbs.

"Because of patent expiries and more established regulatory pathways for approving biosimilars in Europe, most biosimilar MAbs will launch in the EU5 before the United States," said Decision Resources Analyst Cindy Fung, Ph.D. "As a result, U.S. physicians will likely benefit from clinical experience in European markets that will increase their rate of adopting these agents."

The Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German solid-tumor oncologists and hematologist-oncologists to highlight the key expectations that will drive or constrain biosimilar adoption.

About Decision ResourcesDecision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.For more information, contact:Decision ResourcesLisa   Decision Resources, Inc.Christopher Comfort781-993-2597

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions
2. Vermillion Receives Award From the Society of Gynecologic Oncologists
3. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
4. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
5. Society of Gynecologic Oncologists 40th Annual Meeting on Womens Cancer to Include Sessions on Robotics Surgery
6. SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists
7. Society of Gynecologic Oncologists Issues White Paper on HPV Vaccines Impact on Cervical Cancer Prevention
8. Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
9. US Oncology Launches New Flexible Options for Community Oncologists to Join the United Network of US Oncology
10. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):